Search results
Found 30540 matches for
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
Available studentship projects
Applications for this project are now closed.
UCB-Translational Pharmacology Scholarship
The deadline for complete applications is noon on Friday 20 June.We strongly encourage you to submit your applications in advance of the deadline date. Any applications which are not complete by the deadline will not be eligible for consideration.
Themes
OCTRU runs trials across multiple areas of medicine. Within OCTRU there are five core therapeutic areas of expertise, although trials are also undertaken outside of these areas and groups.